Acute Ischemic Stroke occurs when blood flow through a brain artery is blocked by a clot. Clots are either thrombotic or embolic. A thrombotic stroke occurs when a clot forms within an artery within the brain. Whereas an embolic stroke occurs when a clot breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream to be stuck in a narrower vessel in the brain.
Acute Ischemic Stroke Signs & Symptoms
Symptoms of stroke depend upon the severity and placement of stroke in the brain. Some people do not experience any symptoms, while others may experience just one. Most people, however, experience a mixture of symptoms. Symptoms may include paralysis on one side of the body, dizziness, problems with eyesight, etc.
Acute Ischemic Stroke Epidemiology Insights
Several studies recommended that Acute Ischemic Stroke affects adults more commonly as compared to children. The reason will be the increment in the risk factors such as cancer, diabetes, etc. among this population.
As per the association, up to 25% of childhood Ischemic strokes are linked to congenital heart disease. According to a study, the incidence of Acute Ischemic Stroke is greater among women as compared to men.
Acute Ischemic Stroke Treatment Options
Acute Ischemic Stroke treatment consists of a multidisciplinary approach that quite ever requires the involvement of the critical care specialist. Antiplatelet therapy is a foundation of treatment for the prevention of stroke and transient ischemic attacks.
Aspirin is the most ordinarily used agent since it's relatively safe, cheap, and widely available. Considered the gold standard, tissue plasminogen activator, r-tPA, is approved by the Food and Drug Administration to treat ischemic stroke.
Acute Ischemic Stroke Market Insight
The therapeutic market for the treatment of acute ischemic stroke is often divided into two main categories, supported by their mechanism of action: thrombolytics and neuroprotective agents. The current treatment of Acute ischemic stroke is predicated on the restoration of blood flow to the brain by thrombolysis. Additionally, Activase (Genentech) is an approved therapy for the treatment of acute ischemic stroke.
The dynamics of the Acute ischemic stroke market are anticipated to vary in the coming years, due to the development within the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies during the forecast period.
The emerging therapies for the treatment of Acute Ischemic Stroke that are expected to launch in the forecasted period include MultiStem by Athersys/Healios K.K., BMS-986177 by Bristol-Myers Squibb, LT-3001 by Lumosa Therapeutics, Elezanumab by AbbVie, And others.
Sign in to leave a comment.